The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Posting of Offer Document

14 Jan 2010 16:00

RNS Number : 5844F
Proximagen Neuroscience Plc
14 January 2010
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO.

For immediate release

14 January 2010

RECOMMENDED CASH OFFER FOR THE 

ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL

OF MINSTER PHARMACEUTICALS PLC

BY PROXIMAGEN NEUROSCIENCE PLC

Posting of offer document 

On 4 January 2010, the boards of Proximagen Neuroscience plc ("Proximagen") and Minster Pharmaceuticals plc ("Minster") announced the recommended offer by Proximagen for the entire issued and to be issued share capital of Minster (the "Offer"). 

Proximagen announces that an offer document ("Offer Document") and a form of acceptance containing the final terms and conditions of the Offer, will today be posted to eligible Minster Shareholders. 

To accept the Offer:

If you hold Minster Shares in certificated form (that is, not in CREST), the form of acceptance should be completed, signed, witnessed and returned together with your share certificate in accordance with the instructions contained in the Offer Document and the form of acceptance.

If you hold Minster Shares in uncertificated form (that is, in CREST), you should follow the procedure for electronic acceptance through CREST in accordance with the instructions set out in the Offer Document.

The first closing of the Offer is at 1.00 p.m. (London time) on 16 February 2010.

In accordance with Rule 19.11 of the City Code, copies of the Offer Document, the form of acceptance and other documents required to be put on display for the purposes of the Offer will be available for inspection during normal business hours on any weekday (Saturdays, Sundays and public holidays excepted) at the offices of Reed Smith LLP, The Broadgate Tower, 20 Primrose Street, London EC2A 2RS throughout the period during which the Offer remains open for acceptance. A copy of this announcement, the Offer Document and the form of acceptance will also be available free of charge to view, subject to restrictions relating to persons located in jurisdictions where such availability is restricted, on Proximagen's website at www.proximagen.com and on Minster's website at www.minsterpharma.com. In addition, copies of the Offer Document and form of acceptance will be available from the offices of Capita Registrars, Corporate Actions, The Registry, 34 Beckenham Road, Beckenham, Kent BR3 4TU.

If you have any questions relating to the Offer Document, and the completion and return of the Form of Acceptance, please telephone Capita Registrars between 9.00am and 5.00 p.m. (London time) Monday to Friday on 0871 664 0321 from within the UK or +44 20 8639 3399 if calling from outside the UK. Calls to the 0871 664 0321 number cost 10 pence per minute (including VAT) plus your service provider's network extras. Calls to the helpline from outside the UK will be charged at applicable international rates. Different charges may apply to calls from mobile telephones and calls may be recorded and randomly monitored for security and training purposes. The helpline cannot provide advice on the merits of the Offer nor give any financial, legal or tax advice. Completion of the Offer remains subject to the satisfaction or, if permitted, waiver of the conditions to the Offer set out in the Offer Document. 

 

Terms defined in the Offer Document have the same meaning in this announcement.

14 January 2010

Enquiries

For Proximagen

Proximagen Neuroscience plc

Phone: +44 (0)20 7848 6938

Kenneth Mulvany, Chief Executive Officer

James Hunter, Finance Director

Buchanan Communications

Phone: +44 (0)20 7466 5000

Tim Anderson, Catherine Breen

Evolution Securities Limited (NOMAD)

Phone: +44 (0)20 7071 4300

Stuart Andrews, Bobbie Hilliam, Tim Redfern 

For Minster: 

Minster Pharmaceuticals plc

Phone: +44 (0)20 7936 9921

John Russell, Chairman and Interim CEO

Karl Keegan, Chief Financial Officer

Buchanan Communications

Phone: +44 (0)20 7466 5000

Mark Court

Nomura Code Securities Limited 

(Rule 3 Advisers & NOMAD)

Phone: +44 (0)20 7776 1200

Richard Potts, Giles Balleny

This announcement is not intended to, and does not constitute, or form any part of an offer to sell or an invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of an offer to purchase or subscribe for any securities in any jurisdiction, pursuant to the Offer or otherwise. Any acceptance or other response to the Offer should be made only on the basis of information contained in or referred to in the Offer Document and, in respect of Minster Shares held in certificated form, the form of acceptance

Evolution Securities Limited, which is authorised and regulated by the Financial Services Authority is acting as financial adviser and broker to Proximagen and for no-one else in connection with the Offer and will not be responsible to anyone other than Proximagen for providing the protections afforded to customers of Evolution Securities Limited or for affording advice in relation to the Offer or any other matters referred to in this document. 

Nomura Code Securities Limited, which is authorised and regulated by the Financial Services Authority, is acting as financial adviser to Minster and for no-one else in connection with the Offer and will not be responsible to anyone other than Minster for providing the protections afforded to customers of Nomura Code Securities Limited or for affording advice in relation to the Offer or any other matters referred to in this document.

Distribution of Announcement 

 

The distribution of this announcement and the availability of the Offer in jurisdictions other than the United Kingdom may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than the United Kingdom should inform themselves about, and observe, any applicable requirements. This announcement has been made for the purpose of complying with English law and the City Code and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside England and Wales. 

Copies of this announcement are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any jurisdiction where to do so would violate the laws of that jurisdiction and persons receiving this announcement (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send it in, into or from any such jurisdiction. This announcement does not constitute an offer or an invitation to purchase any securities or a solicitation of an offer to buy any securities in any jurisdiction in which such offer or solicitation is unlawful. 

The statements contained herein are made as at the date of this announcement, unless some other time is specified in relation to them, and the issue of this announcement shall not give rise to any implication that there has been no change in the facts set forth herein since that date. Nothing contained herein shall be deemed to be a forecast, projection or estimate of the future financial performances of Minster or Proximagen, except where otherwise stated.

Notice to US investors 

The Offer is being made for securities of an English company and United States investors should be aware that this announcement, the Offer Document and any other documents relating to the Offer have been or will be prepared in accordance with the City Code and UK disclosure requirements, format and style, all of which may differ from those in the United States. Minster's financial statements, and all financial information relating to Minster that is included in this announcement or that may be included in the Offer Document or any other documents relating to the Offer, have been or will be prepared in accordance with UK generally accepted accounting principles and/or International Financial Reporting Standards and thus may not be comparable to financial statements of US companies. 

 

This announcement does not constitute a Tender Offer Statement or a Solicitation/Recommendation Statement under the rules and regulations of the US Securities and Exchange Commission. The Offer will be made in the United States pursuant to applicable US tender offer rules and also in accordance with the requirements of the City Code. 

The receipt of cash pursuant to the Offer by a US holder of Minster Shares will be a taxable transaction for US federal income tax purposes and under applicable US state and local, as well as foreign and other tax laws. Each holder of Minster Shares is urged to consult his independent professional adviser regarding the tax consequences of acceptance of the Offer. 

Minster is incorporated under English law. All or some of the directors of Minster are residents of countries other than the US. As a result, it may not be possible for United States holders of Minster Shares to effect service of process within the US upon Minster or such directors of Minster or to enforce against any of them judgements of the United States predicated upon the civil liability provisions of the federal securities laws of the United States. It may not be possible to sue Minster or its officers or directors in a non-US court for violations of US securities laws. 

 

Dealing Disclosure Requirements

Under the provisions of the Rule 8.3 of the City Code, if any person is, or becomes, "interested" (directly of indirectly) in one per cent. or more of any class of "relevant securities" of Minster, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3:30 p.m. (London Time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Minster, they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant securities" of Minster by Proximagen or Minster, or by any of their respective "associates", must be disclosed by no later than 12:00 noon (London Time) on the London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.

"Interest in securities" arises, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having as "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ODPEZLFFBFFZBBK
Date   Source Headline
4th Dec 20196:17 pmRNSStatement re Creditors' Voluntary Liquidation
20th Nov 20196:00 pmRNSMporium Group
20th Nov 20194:43 pmRNSAppointment of Administrator for Mporium Ltd
20th Nov 20193:03 pmRNSResignation of NOMAD
21st Oct 20197:30 amRNSSuspension - Mporium Group PLC
21st Oct 20197:00 amRNSAdjournment of GM & suspension of trading
30th Sep 20197:01 amRNSProposed acquisition and fundraising
30th Sep 20197:00 amRNSHalf-year Results
26th Sep 20192:00 pmRNSPrice Monitoring Extension
19th Sep 20194:29 pmRNSBlock Admission Six Monthly Return
4th Sep 20197:00 amRNSCommercial Partnership with Click Labs Group
28th Aug 20197:00 amRNSCommercial agreement w/ major media agency network
20th Aug 201911:04 amRNSHolding(s) in Company
20th Aug 20197:00 amRNSHolding(s) in Company
20th Aug 20197:00 amRNSHolding(s) in Company
20th Aug 20197:00 amRNSHolding(s) in Company
15th Aug 20199:20 amRNSIssue of Shares, Warrants and Total Voting Rights
12th Aug 201912:02 pmRNSHolding(s) in Company
30th Jul 20197:00 amRNSPCA Dealing
24th Jul 201910:33 amRNSResult of AGM
23rd Jul 20197:00 amRNSDirectorate Changes and Update on Strategy
11th Jul 20197:00 amRNSSale of Fast Web Media
2nd Jul 20195:36 pmRNSResult of GM - Replacement
2nd Jul 20193:30 pmRNSResult of GM
28th Jun 20197:00 amRNSFinal Results
14th Jun 20197:00 amRNSUpdate on Fundraising and Posting of Circular
11th Jun 201911:05 amRNSSecond Price Monitoring Extn
11th Jun 201911:00 amRNSPrice Monitoring Extension
11th Jun 20197:23 amRNSFundraising, Update on FY results & Biz Structure
3rd Jun 20193:00 pmRNSUpdate on Report and Accounts
15th May 20192:59 pmRNSBlock Listing Return
4th Apr 20197:00 amRNSQ1 Update
20th Mar 20197:00 amRNSContract extension for MporiumX
13th Mar 20192:34 pmRNSHolding(s) in Company
13th Mar 20197:00 amRNSNew agreement for IMPACT
20th Feb 20198:20 amRNSHolding(s) in Company
18th Feb 201912:14 pmRNSHolding(s) in Company
15th Feb 20191:47 pmRNSHolding(s) in Company
15th Feb 201910:39 amRNSHolding(s) in Company
15th Feb 201910:35 amRNSHolding(s) in Company
15th Feb 201910:32 amRNSHolding(s) in Company
15th Feb 201910:25 amRNSHolding(s) in Company
12th Feb 20194:40 pmRNSSecond Price Monitoring Extn
12th Feb 20194:35 pmRNSPrice Monitoring Extension
12th Feb 20197:00 amRNSUpdate on Revenue and the Allay Agreement
11th Feb 201910:04 amRNSResult of General Meeting
8th Feb 20197:00 amRNSNew Agreement for MporiumX
30th Jan 20194:40 pmRNSSecond Price Monitoring Extn
30th Jan 20194:35 pmRNSPrice Monitoring Extension
25th Jan 20197:00 amRNSStrategic Collaboration Agreement & Notice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.